MedTrace Logo

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

NCT04057053 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-01-26

No results posted yet for this study

Summary

Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

Conditions

  • Fuchs' Endothelial Dystrophy
  • Cataract

Interventions

DRUG

Netarsudil 0.02% Ophthalmic Solution

Use of Netarsudil 0.02% ophthalmic solution daily after surgery

Sponsors & Collaborators

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Emma E Davies · Massachusetts Eye and Ear Infirmary

  • Roberto Pineda · Massachusetts Eye and Ear Infirmary

  • Ula Jurkunas · Massachusetss Eye and Ear Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-02
Primary Completion
2020-12-20
Completion
2020-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04057053 on ClinicalTrials.gov